{"transactions":[{"id":873845,"issuer":{"id":1553,"kind":"organization","name":"Generate Biomedicines, Inc.","symbol":"GENB"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T17:47:17.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":29561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":29561,"derivative":{"exercise_price":16,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":29561},"source":{"system":"sec-edgar","filing":"0001193125-26-085871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000119312526085871/ownership.xml","form_type":"4"}},{"id":1486544,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T16:30:09.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":6000,"derivative":{"exercise_price":5.3,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000950170-24-070711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000095017024070711/ownership.xml","form_type":"4"}},{"id":1486543,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T16:30:09.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"source":{"system":"sec-edgar","filing":"0000950170-24-070711","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000095017024070711/ownership.xml","form_type":"4"}},{"id":1869402,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T16:24:58.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":6000,"derivative":{"exercise_price":3.7,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-23-033723","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919123033723/doc4.xml","form_type":"4"}},{"id":1869401,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T16:24:58.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-23-033723","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919123033723/doc4.xml","form_type":"4"}},{"id":1885131,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2023-05-19T20:03:56.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":3454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":3454,"derivative":{"exercise_price":189.87,"exercise_date":"2024-05-18","expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":3454},"source":{"system":"sec-edgar","filing":"0001735276-23-000061","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527623000061/edgardoc.xml","form_type":"4"}},{"id":1990710,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-02-27T21:11:47.000Z","date":"2023-02-23","kind":"exercise","acquired":false,"shares":136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of ALNY common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vested on February 23, 2023, the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vested on February 23, 2023, the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":136},"source":{"system":"sec-edgar","filing":"0001735276-23-000016","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527623000016/edgardoc.xml","form_type":"4"}},{"id":1990709,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:11:47.000Z","date":"2023-02-23","kind":"exercise","acquired":true,"shares":136,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":136,"source":{"system":"sec-edgar","filing":"0001735276-23-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527623000016/edgardoc.xml","form_type":"4"}},{"id":2136965,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T16:07:17.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":6750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":6.12,"underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0000899243-22-033658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924322033658/doc4.xml","form_type":"4"}},{"id":2136964,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T16:07:17.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":8375,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":25.35,"underlying":"Common Stock","underlying_shares":8375},"source":{"system":"sec-edgar","filing":"0000899243-22-033658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924322033658/doc4.xml","form_type":"4"}},{"id":2136963,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T16:07:17.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":17533,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":20,"underlying":"Common Stock","underlying_shares":17533},"source":{"system":"sec-edgar","filing":"0000899243-22-033658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924322033658/doc4.xml","form_type":"4"}},{"id":2136962,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T16:07:17.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":28053,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":5.43,"underlying":"Common Stock","underlying_shares":28053},"source":{"system":"sec-edgar","filing":"0000899243-22-033658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924322033658/doc4.xml","form_type":"4"}},{"id":2136961,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T16:07:17.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":14026,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":5.05,"underlying":"Common Stock","underlying_shares":14026},"source":{"system":"sec-edgar","filing":"0000899243-22-033658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924322033658/doc4.xml","form_type":"4"}},{"id":2136960,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-14T16:07:17.000Z","date":"2022-10-14","kind":"other","acquired":false,"shares":7250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924322033658/doc4.xml","form_type":"4"}},{"id":2136959,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-14T16:07:17.000Z","date":"2022-10-14","kind":"other","acquired":false,"shares":52532,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924322033658/doc4.xml","form_type":"4"}},{"id":2155456,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-09-19T17:13:35.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022."}],"balance_after":12000,"derivative":{"exercise_price":7.349,"expiration_date":"2032-09-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-050554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919122050554/doc4.xml","form_type":"4"}},{"id":2155455,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-19T17:13:35.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-22-050554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919122050554/doc4.xml","form_type":"4"}},{"id":2229821,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T20:56:10.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date."}],"balance_after":20000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001140361-22-023333","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000114036122023333/form4.xml","form_type":"4"}},{"id":2237548,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T17:31:49.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":6750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 8, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":6750,"derivative":{"exercise_price":6.12,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0000899243-22-021660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924322021660/doc4.xml","form_type":"4"}},{"id":2237547,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T17:31:49.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock."}],"balance_after":59782,"source":{"system":"sec-edgar","filing":"0000899243-22-021660","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924322021660/doc4.xml","form_type":"4"}},{"id":2247235,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-02T19:07:35.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":17500,"derivative":{"exercise_price":0.78,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-033708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919122033708/doc4.xml","form_type":"4"}},{"id":2262170,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2022-05-20T20:05:38.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":5153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":5153,"derivative":{"exercise_price":128.31,"exercise_date":"2023-05-18","expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":5153},"source":{"system":"sec-edgar","filing":"0001735276-22-000049","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000049/edgardoc.xml","form_type":"4"}},{"id":2372511,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-02-25T21:10:20.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of ALNY common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":136,"derivative":{"underlying":"Common Stock","underlying_shares":136},"source":{"system":"sec-edgar","filing":"0001735276-22-000032","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527622000032/edgardoc.xml","form_type":"4"}},{"id":2630872,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2021-07-19T20:19:51.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":4032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date."}],"balance_after":4032,"derivative":{"exercise_price":171.95,"exercise_date":"2022-07-15","expiration_date":"2031-07-14","underlying":"Common Stock","underlying_shares":4032},"source":{"system":"sec-edgar","filing":"0001735276-21-000065","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000065/edgardoc.xml","form_type":"4"}},{"id":2653253,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T17:25:47.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":3.97,"expiration_date":"2031-06-24","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-21-022578","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000114036121022578/form4.xml","form_type":"4"}},{"id":2660671,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T19:04:01.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":8375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 17, 2022 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":8375,"derivative":{"exercise_price":25.35,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":8375},"source":{"system":"sec-edgar","filing":"0000899243-21-025091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924321025091/doc4.xml","form_type":"4"}},{"id":2660670,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T19:04:01.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock."}],"balance_after":55282,"source":{"system":"sec-edgar","filing":"0000899243-21-025091","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924321025091/doc4.xml","form_type":"4"}},{"id":2673759,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-10T17:28:20.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":17500,"derivative":{"exercise_price":6.3,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-21-039576","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919121039576/doc4.xml","form_type":"4"}},{"id":3089168,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2020-07-06T20:52:03.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":4581,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4581,"derivative":{"exercise_price":148.77,"exercise_date":"2021-07-01","expiration_date":"2030-07-01","underlying":"Common Stock","underlying_shares":4581},"source":{"system":"sec-edgar","filing":"0001735276-20-000079","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000079/edgardoc.xml","form_type":"4"}},{"id":3100756,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Enterprise 5 Junior Stock","published_at":"2020-06-24T21:23:36.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":14026,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of  0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii)  9,847 shares of Enterprise 3 Junior Stock at a conversion rate of  0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of  0.7585  shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of  0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-017609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924320017609/doc4.xml","form_type":"4"}},{"id":3100755,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Enterprise 4 Junior Stock","published_at":"2020-06-24T21:23:36.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":10240,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of  0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii)  9,847 shares of Enterprise 3 Junior Stock at a conversion rate of  0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of  0.7585  shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of  0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-017609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924320017609/doc4.xml","form_type":"4"}},{"id":3100754,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Enterprise 3 Junior Stock","published_at":"2020-06-24T21:23:36.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":9847,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of  0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii)  9,847 shares of Enterprise 3 Junior Stock at a conversion rate of  0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of  0.7585  shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of  0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-017609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924320017609/doc4.xml","form_type":"4"}},{"id":3100753,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Enterprise 2 Junior Stock","published_at":"2020-06-24T21:23:36.000Z","date":"2020-06-23","kind":"sale","acquired":false,"shares":33781,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of  0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii)  9,847 shares of Enterprise 3 Junior Stock at a conversion rate of  0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of  0.7585  shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of  0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-017609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924320017609/doc4.xml","form_type":"4"}},{"id":3100752,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-24T21:23:36.000Z","date":"2020-06-23","kind":"purchase","acquired":true,"shares":52532,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of  0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii)  9,847 shares of Enterprise 3 Junior Stock at a conversion rate of  0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of  0.7585  shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of  0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock."}],"balance_after":52532,"source":{"system":"sec-edgar","filing":"0000899243-20-017609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924320017609/doc4.xml","form_type":"4"}},{"id":3102981,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-22T19:34:38.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":17533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this stock option shall vest upon the earlier of June 18, 2021 or the date of the next annual shareholder meeting of the Issuer following the date of grant."}],"balance_after":0,"derivative":{"exercise_price":20,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":17533},"source":{"system":"sec-edgar","filing":"0000899243-20-017439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000089924320017439/doc4.xml","form_type":"4"}},{"id":3105312,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-18T16:18:43.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":4.46,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-037580","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919120037580/doc4.xml","form_type":"4"}},{"id":3113425,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T16:51:54.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":17500,"derivative":{"exercise_price":9.17,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-20-035966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919120035966/doc4.xml","form_type":"4"}},{"id":3361384,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T21:06:22.000Z","date":"2019-11-20","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018."}],"balance_after":0,"derivative":{"exercise_price":30.09,"exercise_date":"2014-06-06","expiration_date":"2023-06-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001735276-19-000100","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000100/edgardoc.xml","form_type":"4"}},{"id":3361383,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T21:06:22.000Z","date":"2019-11-20","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018."}],"balance_after":0,"derivative":{"exercise_price":9.3,"exercise_date":"2012-06-09","expiration_date":"2021-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001735276-19-000100","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000100/edgardoc.xml","form_type":"4"}},{"id":3361382,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-11-22T21:06:22.000Z","date":"2019-11-20","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018."}],"balance_after":0,"derivative":{"exercise_price":11.33,"exercise_date":"2013-06-21","expiration_date":"2022-06-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001735276-19-000100","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000100/edgardoc.xml","form_type":"4"}},{"id":3361381,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-11-22T21:06:22.000Z","date":"2019-11-20","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":9.14,"expiration_date":"2020-12-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001735276-19-000100","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000100/edgardoc.xml","form_type":"4"}},{"id":3361380,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-22T21:06:22.000Z","date":"2019-11-20","kind":"sale","acquired":false,"shares":75000,"price":100,"value":7500000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001735276-19-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000100/edgardoc.xml","form_type":"4"}},{"id":3361379,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-22T21:06:22.000Z","date":"2019-11-20","kind":"exercise","acquired":true,"shares":15000,"price":30.09,"value":451350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001735276-19-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000100/edgardoc.xml","form_type":"4"}},{"id":3361378,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-22T21:06:22.000Z","date":"2019-11-20","kind":"exercise","acquired":true,"shares":15000,"price":11.33,"value":169950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001735276-19-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000100/edgardoc.xml","form_type":"4"}},{"id":3361377,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-22T21:06:22.000Z","date":"2019-11-20","kind":"exercise","acquired":true,"shares":15000,"price":9.3,"value":139500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001735276-19-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000100/edgardoc.xml","form_type":"4"}},{"id":3361376,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-22T21:06:22.000Z","date":"2019-11-20","kind":"exercise","acquired":true,"shares":30000,"price":9.14,"value":274200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001735276-19-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000100/edgardoc.xml","form_type":"4"}},{"id":3471615,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2019-07-02T20:05:02.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9000,"derivative":{"exercise_price":72.01,"exercise_date":"2020-07-01","expiration_date":"2029-06-30","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001735276-19-000060","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000060/edgardoc.xml","form_type":"4"}},{"id":3492554,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (right to buy)","published_at":"2019-06-12T16:15:19.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":11000,"derivative":{"exercise_price":5.6,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-19-036359","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919119036359/doc4.xml","form_type":"4"}},{"id":3502077,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-04T16:56:06.000Z","date":"2019-06-01","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":13.95,"expiration_date":"2029-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-034373","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919119034373/doc4.xml","form_type":"4"}},{"id":3564581,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2019-04-03T22:02:50.000Z","date":"2019-04-01","kind":"disposition_to_issuer","acquired":false,"shares":4056,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. (\"Cyclerion\") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock."}],"balance_after":132663,"source":{"system":"sec-edgar","filing":"0001209191-19-023411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119023411/doc4.xml","form_type":"4"}},{"id":3564344,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T21:08:43.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":3279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Cyclerion common stock granted to the reporting person as a result of adjustments to existing Ironwood shares of common stock made in connection with the Separation."}],"balance_after":16950,"source":{"system":"sec-edgar","filing":"0001209191-19-023565","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919119023565/doc4a.xml","form_type":"4/A","original_submission_date":"2019-04-01"}},{"id":3564343,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T21:08:43.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":13671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the separation (the \"Separation\") of Cyclerion Therapeutics, Inc. (\"Cyclerion\") from Ironwood Pharmaceuticals, Inc. (\"Ironwood\"), the reporting person received Cyclerion shares representing an equitable adjustment of Ironwood shares held by the reporting person prior to the Separation."}],"balance_after":13671,"source":{"system":"sec-edgar","filing":"0001209191-19-023565","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919119023565/doc4a.xml","form_type":"4/A","original_submission_date":"2019-04-01"}},{"id":3564342,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T19:32:05.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":3279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Cyclerion common stock granted to the reporting person as a result of adjustments to existing Ironwood shares of common stock made in connection with the Separation."}],"balance_after":16950,"source":{"system":"sec-edgar","filing":"0001209191-19-023507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919119023507/doc4.xml","form_type":"4"}},{"id":3564341,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T19:32:05.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":13671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the separation (the \"Separation\") of Cyclerion Therapeutics, Inc. (\"Cyclerion\") from Ironwood Pharmaceuticals, Inc. (\"Ironwood\"), the reporting person received Cyclerion shares representing an equitable adjustment of Ironwood shares held by the reporting person prior to the Separation."}],"balance_after":13671,"source":{"system":"sec-edgar","filing":"0001209191-19-023507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000120919119023507/doc4.xml","form_type":"4"}},{"id":3708589,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2019-01-04T00:59:27.000Z","date":"2018-12-31","kind":"other","acquired":true,"shares":44863,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation."}],"balance_after":136719,"source":{"system":"sec-edgar","filing":"0001209191-19-001491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119001491/doc4.xml","form_type":"4"}},{"id":3708588,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2019-01-04T00:59:27.000Z","date":"2018-12-31","kind":"other","acquired":false,"shares":44863,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-001491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119001491/doc4.xml","form_type":"4"}},{"id":3885264,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2018-06-22T20:18:38.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9000,"derivative":{"exercise_price":105.26,"exercise_date":"2019-06-20","expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001735276-18-000029","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000029/edgardoc.xml","form_type":"4"}},{"id":3892306,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-15T16:28:36.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":11000,"derivative":{"exercise_price":12.95,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001179110-18-008619","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000117911018008619/edgar.xml","form_type":"4"}},{"id":3908256,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2018-06-04T21:27:53.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":16223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Plan, effective as of January 2014."}],"balance_after":91856,"source":{"system":"sec-edgar","filing":"0001209191-18-035246","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919118035246/doc4.xml","form_type":"4"}},{"id":4203044,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-22T17:19:23.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":11000,"derivative":{"exercise_price":14.62,"expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001179110-17-012627","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000117911017012627/edgar.xml","form_type":"4/A","original_submission_date":"2017-06-12"}},{"id":4285397,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-12T16:04:02.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":11000,"derivative":{"exercise_price":14.26,"expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001179110-17-008900","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000117911017008900/edgar.xml","form_type":"4"}},{"id":4291299,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2017-06-06T20:56:44.000Z","date":"2017-06-02","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11250,"derivative":{"exercise_price":71.99,"exercise_date":"2018-06-02","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001553878-17-000024","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000024/edgardoc.xml","form_type":"4"}},{"id":4295695,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2017-06-02T20:58:51.000Z","date":"2017-05-31","kind":"grant","acquired":true,"shares":15625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Plan, effective as of January 2014."}],"balance_after":75633,"source":{"system":"sec-edgar","filing":"0001209191-17-037351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919117037351/doc4.xml","form_type":"4"}},{"id":4599872,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63920,"kind":"person","name":"Fanucci Marsha","position":1,"cik":"0001298814","reported_name":"Fanucci Marsha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-09-19T06:54:36.000Z","date":"2016-09-15","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Ms. Fanucci's continued service as a director through each applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":12.59,"expiration_date":"2026-09-14","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-16-145300","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1298814/000110465916145300/a4.xml","form_type":"4"}}]}